# Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

> **NCT02914600** · PHASE3 · TERMINATED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 1188 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02914600
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-17
- **Primary completion:** 2023-08-01
- **Final completion:** 2023-08-01
- **Target enrollment:** 1188 (ACTUAL)
- **Why stopped:** development program for filgotinib for participants with Crohn's disease has been stopped
- **Last updated:** 2024-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914600, "Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02914600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*